<SEC-DOCUMENT>0001144204-17-036994.txt : 20170717
<SEC-HEADER>0001144204-17-036994.hdr.sgml : 20170717
<ACCEPTANCE-DATETIME>20170717163254
ACCESSION NUMBER:		0001144204-17-036994
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170712
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170717
DATE AS OF CHANGE:		20170717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEXX LABORATORIES INC /DE
		CENTRAL INDEX KEY:			0000874716
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010393723
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19271
		FILM NUMBER:		17967816

	BUSINESS ADDRESS:	
		STREET 1:		ONE IDEXX DRIVE
		CITY:			WESTBROOK
		STATE:			ME
		ZIP:			04092-2041
		BUSINESS PHONE:		2075560300

	MAIL ADDRESS:	
		STREET 1:		ONE IDEXX DRIVE
		CITY:			WESTBROOK
		STATE:			ME
		ZIP:			04092-2041

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEXX CORP / DE
		DATE OF NAME CHANGE:	19600201
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v470599_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 3.3pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<FONT STYLE="text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest
event reported): <B>July 12, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IDEXX LABORATORIES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Exact name of registrant as specified
in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19271</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>01-0393723</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State or other jurisdiction of incorporation)</I></FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Commission File Number)</I></FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(IRS Employer Identification No.)</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; font-weight: bold; text-align: center; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">One IDEXX Drive, Westbrook, Maine</FONT></TD>
    <TD STYLE="width: 50%; padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>04092</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address of principal executive offices)</I></FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(ZIP Code)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>207.556.0300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Registrant's telephone number, including
area code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Former name or former address, if changed
since last report)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0; font-size: 10pt; text-align: left; layout-grid-mode: line; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: left; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 3.3pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 3.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 3.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; font-size: 10pt; text-indent: 0; layout-grid-mode: line; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.02</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0; layout-grid-mode: line; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;&nbsp;Compensatory Arrangements of Certain Officers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Election of New
Director. </I></B> On July 12, 2017, the board of directors (the &ldquo;Board&rdquo;) of IDEXX Laboratories, Inc. (the &ldquo;Company&rdquo;)
elected Stuart M. Essig, PhD as an independent Class III Director effective that date. To accommodate Dr. Essig&rsquo;s election
as a Class III Director, the Board increased the number of Directors constituting the Board from eight to nine and the number of
Class III Directors from two to three. It is expected that Dr. Essig will stand for election by stockholders as a Class III Director
at the Company&rsquo;s 2019 annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Essig has not yet
been named to any Board committee and, as of the date hereof, it has not been determined to which Board committees, if any, Dr.
Essig will be named.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no related
person transactions (or proposed related person transactions) with respect to Dr. Essig reportable under Item 5.02(d) of Form 8-K
and Item 404(a) of Regulation S-K since the beginning of the Company&rsquo;s last fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Essig will receive
the same compensation as is paid to the Company&rsquo;s other nonemployee Directors as described in the section entitled &ldquo;Corporate
Governance &ndash; Director Compensation&rdquo; in the Company&rsquo;s Proxy Statement filed with the Securities and Exchange Commission
on March 23, 2017, which description is incorporated herein by reference. The cash fee to be paid to Dr. Essig in the third
quarter of 2017 will be prorated to reflect the effective date of his election to the Board on July 12, 2017. <FONT STYLE="background-color: white">Annual
deferred stock unit and stock option grants were made to nonemployee Directors on May 3, 2017, the date of the Company&rsquo;s
2017 annual meeting of stockholders. Since Dr. Essig was not serving as a Director at that time, such grants will be made to him
on September 1, 2017, and the award values will be prorated to reflect the portion of the year during which he will serve on the
Board, specifically from the effective date of his election on July 12, 2017 until the Company&rsquo;s 2018 annual meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 17, 2017, the
Company issued a press release regarding Dr. Essig&rsquo;s election to the Board. A copy of the press release is furnished as Exhibit
99.1 to this Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following exhibit relating
to Item 5.02 shall be deemed to be furnished, and not filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 0.5in; padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; layout-grid-mode: line; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release entitled &ldquo;IDEXX Laboratories Elects Stuart M. Essig to Board of Directors&rdquo; and dated July 17, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IDEXX LABORATORIES, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; padding: 0; font-weight: normal; text-align: left; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 17, 2017</FONT></TD>
    <TD STYLE="width: 3%; padding: 0; font-weight: normal; text-align: left; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; padding: 0; font-weight: normal; text-align: left; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jacqueline L. Studer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacqueline L. Studer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Vice President, General Counsel and Secretary </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; padding: 0; layout-grid-mode: line; text-decoration: underline; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 0.25in; padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-decoration: underline; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description of Exhibit</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release entitled &ldquo;IDEXX Laboratories Elects Stuart M. Essig to Board of Directors&rdquo; and dated July 17, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v470599_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">
<p style="text-align:center"><b>IDEXX Laboratories Elects Stuart M. Essig to Board of Directors</b></p></div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p></p><p>WESTBROOK, Maine, July 17, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced the unanimous election of Stuart M. Essig as a member of the Company&#39;s Board of Directors, effective July 12, 2017. In connection with Dr. Essig&#39;s election, the Board also increased its size from 8 to 9 members, effective July 12, 2017.</p><p>Dr. Essig has been the Chairman of the Board of Directors of Integra LifeSciences Holdings Corporation since 2012, and he served as Integra&#39;s Chief Executive Officer from 1997 until 2012, building Integra into a leading global surgical
products company. He has also served since 2012 as Managing Director of Prettybrook Partners LLC, a private investment firm focused on the healthcare industry. In addition to Integra, Dr. Essig currently serves on the Boards of Directors of SeaSpine Holdings Corporation and Owens &amp; Minor, Inc. and is the Chairman of the Board of Directors of Breg, Inc., a private company offering nonsurgical orthopedic care products and solutions. He previously served on the Boards of Directors of St. Jude Medical Corporation from 1999 to 2017, prior to its sale to Abbott Corporation, and Zimmer Biomet Holdings, Inc. from 2005 to 2008. </p><p>&#34;We are excited to welcome Stuart to our Board of Directors,&#34; said Jonathan Ayers, the Company&#39;s Chairman and Chief Executive Officer. &#34;Stuart brings extensive executive management experience and deep strategic expertise in the global healthcare
industry, and he has served on the boards of several private and public companies. Stuart&#39;s perspective and insight will further strengthen our Board&#39;s already broad and diverse capabilities and experiences and be extremely valuable to IDEXX as we continue our growth trajectory as a global leader in pet healthcare innovation.&#34;</p><p>&#34;IDEXX&#39;s business model of enduring growth through innovation in a highly attractive, expanding industry has yielded strong returns,&#34; said Dr. Essig. &#34;I look forward to working with my fellow Board members to support extending IDEXX&#39;s successful track record of strong organic growth and building exceptional long-term value for our shareholders.&#34;</p><p>Before joining Integra in 1997, Dr. Essig was a managing director in mergers and acquisitions for Goldman, Sachs and Co., specializing in the medical device, pharmaceutical
and biotechnology sectors. Dr. Essig has also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association. Dr. Essig holds an A.B. from Princeton University and an M.B.A. and Ph.D. in financial economics from the University of Chicago. </p><p><b>About IDEXX Laboratories
<br /></b>IDEXX Laboratories, Inc. is a member of the S&amp;P 500<sup>&#174;</sup> Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 7,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: www.idexx.com.</p><p><b>Note Regarding Forward-Looking Statements
<br /></b><i>This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. </i><i>Forward-looking statements can be identified by the use of words such as &#34;expects,&#34; &#34;may,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;would,&#34; &#34;will,&#34; &#34;plans,&#34; &#34;believes,&#34; &#34;estimates,&#34; &#34;should,&#34; and similar words and expressions. These forward-looking statements are based on management&#39;s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the
Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company&#39;s filings with the United States Securities and Exchange Commission (which are available from the SEC&#39;s EDGAR database at www.sec.gov/, at various SEC reference facilities in the United States and via the Company&#39;s website at </i>www.idexx.com<i>).</i></p><p>Contact: </p><p><b>Investor Relations:
<br /></b>Kerry Bennett
<br />207-556-8155</p><p><img src="idexxlaboratoriesinclog.jpg" title="idexxlaboratoriesinclog.jpg"></p><p> </p>
<br /><br /></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>idexxlaboratoriesinclog.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 idexxlaboratoriesinclog.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" 0$" 0$! @(" @(" @(" 0(" @(" @(" @+_
MVP!# 0$! 0$! 0$! 0$" 0$! @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @+_P  1" !* 9 # 2(  A$! Q$!_\0
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MQ>W]]=R&6>XFE;U=B%50J1HJQQHD:(BY-%'Z_P">O^?2MC$0D*"Q( 4$DGH
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M (1'CS_YFJ/^'L/[#7_17)__  B/'G_S-5Y_^MO#/_11X+_PJH__ "9]9_Q
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MX7_^IUH%?UP5E/=>AI3ZA17\W/B/]O\ _:OL/$6OV%I\2[:*UL==UBRMHO\
MA"_!4GEV]KJ5S!!'ODT$L^V*-!EB6.W)).2<?_AX5^UM_P!%.M?_  B/ _\
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M^1_X'?\ );_@K_V6#X7_ /J=:!7]<%93W7H:4^I_'AXO_P"1N\5_]C/XA_\
M3Q>5SU=#XO\ ^1N\5_\ 8S^(?_3Q>5SU:1V7H9GLG[/&MZ/X:^.OPD\0^(=3
ML=%T/1?'OAW4=6U;4[F*ST_3;"UOHY+F\O+J=@EO;)&"69B  ,U_2#_PUY^R
MY_T<#\)/_"YT#_Y-K^5K^O\ 2BDXIN[*C)QTL?U2_P##7G[+G_1P/PD_\+G0
M/_DVC_AKS]ES_HX'X2?^%SH'_P FU_*U12Y%W8_:/L?U2_\ #7G[+G_1P/PD
M_P#"YT#_ .3:4?M=?LNMD+\?_A*QP3@>.= ).!DX'VVOY6:*.1=P]H^Q_17\
M6O\ @I!^S_X$T^Z@\$ZI=?%3Q28)#9V'ARUN[;P]!/\ N_(DU7Q3J%O';O:L
MKRMC3_M\P-N8Y8X-Z.?P:^+/Q1\4_&7X@>(_B+XPGCDUGQ#>>;]GMPZV.EZ?
M BV^F:1IZ2.S+9VUE%%&NXEG(:1SO=J\Y]O\_P#UJ*<8J/J)R;W"BBOI#]EK
M]GS6/VB_BGI?A2**[@\(:5+:ZO\ $#6K9DA.F>&XYQYMI;7,H*QZO?,CVMH
MLC(TKW)B>*VE%4W9-]B5JTNY^]7[#'A*Z\'_ ++GPKL[V#[-=:SI5YXK:+]T
M?]'\4:G>:SITV^&9UE673+JRF4Y!VS@,BL"H_'#_ (*/?\G6>,?^P!X*_P#4
M9T^OZ/K6UM;&UMK*RMH+.RLX(;6TM+6&.WM;6UMXUAM[:VMX5"00)$B*B* J
MJH50  *_G!_X*/?\G6>,?^P!X*_]1G3ZRAK)LTJ=#X4HHHK78S/ZR/V<,_\
M#/'P&X_YHQ\+OP_XH?0NO->T>O/_ -:OXWEU34T18TU&^1$541$N[A41% 54
M15DPJA0  . !@4O]K:K_ -!/4/\ P-N?_CE9^S\RU.R2ML?V045_&_\ VMJO
M_03U#_P-N?\ XY1_:VJ_]!/4/_ VY_\ CE'L_,?M/(_L@H(!X-?QO_VMJO\
MT$]0_P# VY_^.4?VMJO_ $$]0_\  VY_^.4>S\P]IY']D%' ]A7\;_\ :VJ_
M]!/4/_ VY_\ CM?TE_\ !/B:6?\ 96\ 232R32->>*PTDTC2R''B;5  7<DG
M ]3^E3*-E>]QQE=VL?:M?"?[:?[8&F_L\^'%\+^$KJQU#XO^);1GTG3W1;Q/
M">D2I-&?%>L6YC:+?YZ;+&VG(^U2J\ICFMK:X4]S^UE^U/X:_9L\%M,KV&L?
M$C7[>1/!GA&:60F9BS0R:]K$=NZR6_AZVD5M[;HVN)5%M"ZNS/'_ #1>*O%7
MB3QQXCUCQ=XPUJ^\0^)O$%]-J6LZQJ+A[B\O)CR1&BK':VT:!8X+>%([>V@A
MBM[:**"*.-'&-]]@G*RLMV9NIZIJ6MZC?ZQK&H7NK:OJEW/?ZIJNIW,U]J.H
MW]U(T]U>7U[<NTEU=23.[2.[,S,Y)8DDFC11^..">2 , $DY)]O\DC.ID7=-
MTW4-9U&PT?2+&[U/5=5O+?3]-TVPMY;N]O[Z[E6&VM+2U@1GN+B25U5412Q)
MX%?;_P <_P!@_P")/P6^$OA3XG7%Q'KDQLD_X6?X>L$%S<^!;^\FEDL+BWN[
M,21:QHT=N\-KJ$R.!:WL:R0/>V-P]Q9_>7_!/O\ 8^_X0+3;'XX?$FQN$\<Z
MU:3'P=X<OK>2V/A+1+R,Q'5-0MYL/)XBO+<L4#JJVEK/M"M-*TB?J1?65EJ5
MG=Z=J-I;7^GW]M/97UC>V\5U9WMG=1-!=6EW;3HR7%K+ [I)&ZE'1RK @D5G
M*>NFR_$T4-'?=G\;/3CN.O7@T5]S?ML_LF7G[/?C)_$7A+3[Z;X/^*KMFT"\
M)GO8_">J3&263P=J=[-(\I5$1GT^>X8O<VRF,RW%S:W,A^&:T3NK]S-JS:['
MM7P#^.GC#]GSXA:;XZ\*2?:8DQ9>(?#T]Q+#IWB70II$:[TR\,8;9*"HDMIM
MCFWN(TE". R-_3[\)?BQX+^-?@;1_B#X"U%K_0]6C*20W")!J>C:G $&H:%K
M=FDKBSU>UE<)*BO)$X*S6\L]M+!/+_(Q7TY^RW^TQXG_ &:_'BZY8K/JW@W7
M&MK/QQX5$_EQZIIT4A,>HZ>DDBQ0^(K1'F-I*Y56$LEO(Z0S.RQ*-]5N5&5G
M;HS^I2L/Q+XDT+P=H&K^*/$^JV>B>']"L9]2U?5M0E$-I8V5LF^6:5L$L>@5
M%#.[,J(K.RJ<+PK\2O _C3P'8?$SP_XDTVZ\#ZAI$FMIX@GG6RLK33[>-Y+Z
M34VO"ATN2V,4ZW4<_EO;/;R),$9& _ ?]M[]L2_^/?B%O W@;4;FR^#OAN_D
M>$0>;:R?$#5H&6.'Q#JZNJR'18"DITRR8(F9VO;R.2Z%DNGYI-O0TE)+U."_
M:[_:R\1?M*>*Q:61OM%^%OAR_N7\(>&9)"C7\V9;=?%?B*!#MGUZ6T8B&)C*
MFFP7,EO;,&GO9[SX]_QS_DT45NE;1&+=]6'^>H_S_G\_L?\ 90_8^\4?M,W'
MB346OKGPGX'T.QU"RC\7R6 O+>]\8M: Z7HUG:O+&;^*&2:WN-0\MU\J!5A\
MR*>YA:N!_9F_9W\2_M(?$6T\):4\NE^&]-\G4O&WBC[.\T&A:)YA!CMR4\N7
M7+MHVALH78 OOG<-#;RU_3OX!\"^&/AIX/T#P-X/TY-+\.^'-/BT_3[527E*
M)EY;B[G8;KF^FG>66:5OFDEF=SC=BHE*VBW*C&^KV1_)G\0OA]XL^%OC#7?
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M_P"@9I__ (!6W_QNC^R=*_Z!FG_^ 5M_\;I@>+T5[1_9.E?] S3_ /P"MO\
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M)IWEFDX*O:/[)TK_ *!FG_\ @%;?_&Z/[)TK_H&:?_X!6W_QNGL(\7K]7_\
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65N5>"4 G#*P(SUJ9)-/R*BVFO,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C , # 2(  A$! Q$!_\0
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M@SQT8>M8?B+PR\=VDFFVTC1R#+*@)"FH-!TG4[/6K:9[29$#X8E2  >#^AH
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MO+N:^N7N)W+2.<DFNF\*^'O/=;^[3]TI_=HP^\?7Z5J<9-_PGA_Z!X_[^_\
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KC!!Z$444AGE6IP10ZI=1QH%1)6"CT&:--FDM=0@D@<H^\#(],T44Q'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
